Lakefront Biotherapeutics NV (LKFT) financial statements and ratios from SEC XBRL: revenue $1.1B (TTM), net margin 28.9%, revenue growth 303.5% YoY, P/E 6.0. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $1.11B |
| Revenue (TTM) | $1.1B |
| Net Margin | 28.9% |
| Return on Equity | 9.9% |
| Operating Margin (TTM) | 26.5% |
| Current Ratio | 20.15 |
| Interest Coverage | 285.3 |
| Revenue Growth (YoY) | 303.5% |
| EPS Growth (YoY) | 334.8% |
| P/E Ratio | 6.0 |
| Price / Book | 0.60 |
| Price / Sales | 1.74 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
LKFT overview · LKFT earnings · LKFT KPIs · LKFT documents · LKFT ownership · LKFT peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.